Acasti Pharma (ACST)
(Delayed Data from NSDQ)
$2.47 USD
+0.05 (2.07%)
Updated Aug 15, 2024 11:43 AM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Cash flow Statements
Fiscal Year End for Acasti Pharma, Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -12.85 | -42.43 | -9.82 | -19.68 | -25.51 |
Depreciation/Amortization & Depletion | 0.01 | 0.12 | 0.00 | 0.92 | 2.32 |
Net Change from Assets/Liabilities | -1.28 | 0.18 | -2.79 | -5.95 | -3.21 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.79 | 26.21 | -4.63 | 10.38 | 3.46 |
Net Cash From Operating Activities | -12.33 | -15.91 | -17.23 | -14.32 | -22.94 |
Property & Equipment | 0.09 | -0.02 | 0.00 | -0.07 | -0.32 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 6.57 | 13.17 | -3.52 | -9.79 | 8.46 |
Other Investing Activities | -6.55 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.10 | 13.15 | -3.52 | -9.86 | 8.14 |
Uses of Funds
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 7.36 | 0.30 | 0.00 | 59.63 | 14.73 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | -1.56 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | -0.14 | 0.00 |
Net Cash from Financing Activities | 7.36 | 0.30 | 0.00 | 59.49 | 13.18 |
Effect of Exchange Rate Changes | 0.00 | -0.01 | 0.15 | 1.39 | -1.00 |
Net Change In Cash & Equivalents | -4.87 | -2.46 | -20.60 | 36.70 | -2.63 |
Cash at Beginning of Period | 27.88 | 30.34 | 50.94 | 14.24 | 16.87 |
Cash at End of Period | 23.01 | 27.88 | 30.34 | 50.94 | 14.24 |
Diluted Net EPS | -1.35 | -5.70 | -1.62 | -8.16 | -14.40 |
Fiscal Year End for Acasti Pharma, Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -12.85 | -9.69 | -7.30 | -4.02 |
Depreciation/Amortization & Depletion | NA | 0.01 | 0.01 | 0.01 | 0.01 |
Net Change from Assets/Liabilities | NA | -1.28 | -1.98 | -2.49 | -2.03 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 1.79 | 1.42 | 1.42 | -0.20 |
Net Cash From Operating Activities | NA | -12.33 | -10.25 | -8.35 | -6.24 |
Property & Equipment | NA | 0.09 | 0.11 | 0.11 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 6.57 | -6.55 | 0.00 | 0.00 |
Other Investing Activities | NA | -6.55 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 0.10 | -6.44 | 0.11 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 7.36 | 7.36 | 7.36 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 7.36 | 7.36 | 7.36 | 0.00 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -4.87 | -9.33 | -0.88 | -6.24 |
Cash at Beginning of Period | NA | 27.88 | 27.88 | 27.88 | 27.88 |
Cash at End of Period | NA | 23.01 | 18.55 | 26.99 | 21.63 |
Diluted Net EPS | -0.24 | -0.17 | -0.21 | -0.43 | -0.54 |